NEW YORK (GenomeWeb News) – Agilent Technologies said today that French biotech firm Imaxio has achieved Certified Service Provider status for the SureSelect Target Enrichment System for next-generation sequencing.

Imaxio was already a CSP for Agilent's microarray services and participated in comprehensive on-site training and passed a set of requirements demonstrating expertise and skill to receive CSP status for the SureSelect system, Agilent said. SureSelect is compatible with major NGS platforms, such as Illumina, Life Technologies' SOLiD, and Roche's 454.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.